Navigation Links
US Oncology Appoints Glen Laschober EVP & Chief Operating Officer
Date:12/5/2007

HOUSTON, Dec. 5 /PRNewswire/ -- US Oncology, the nation's leading oncology services company, today named Glen Laschober as the company's new executive vice president and chief operating officer. The appointment becomes effective on January 2, 2008.

"Glen's Fortune 500 operating experience, combined with his work in large diversified healthcare organizations, greatly strengthens our existing operating team," said Bruce Broussard, president of US Oncology. "His proven success in working with physicians and healthcare professionals, in areas such as care management programs, process efficiency and leadership development, will accelerate the implementation of our company's initiatives, such as Practice and Quality Efficiency (PQE) and Comprehensive Disease Management, including Cancer Care Pathways."

"I am very pleased to join US Oncology. The company has many exciting opportunities to continue its strong growth as a leading oncology services provider," said Laschober. "Just as importantly, their mission is very compelling to me. Cancer is a devastating disease that touches the lives of a large number of people. I welcome the opportunity to help improve the quality of life for cancer patients and their families."

Laschober brings to US Oncology more than 30 years of healthcare operations experience. Most recently, he served as the chief operating officer for Omnicare, a Fortune 500 healthcare company with revenues of $6.5 billion. He has also been an executive operating officer in several other highly successful organizations such as CVS, Provantage, and Caremark. He began his healthcare career in a variety of engineering and technology operations positions working with medical devices and pharmaceutical products at G.D. Searle, Inc, currently a division of Pfizer. He graduated from the University of Illinois with a B.S. in Engineering, and from the University of Chicago with an M.B.A. in Finance.

He will be based at the company's headquarters in Houston, Texas and will report to Broussard.

About US Oncology, Inc.

US Oncology, headquartered in Houston, Texas, supports one of the nation's largest cancer treatment and research networks. US Oncology provides extensive services and support to its affiliated cancer care sites nationwide to help them expand their offering of the most advanced treatments and technologies, build integrated community-based cancer care centers, improve their therapeutic drug management programs and participate in many of the new cancer-related clinical research studies. US Oncology is affiliated with 1,164 physicians operating in 443 locations, including 91 radiation oncology facilities in 39 states.


'/>"/>
SOURCE US Oncology, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. Genomic Health Announces Multiple Studies on Oncotype DX(TM) Presented at 2007 American Society of Clinical Oncology (ASCO) Breast Cancer Symposium
2. ESMO, Oxford Journals and the Japanese Society of Medical Oncology announce collaboration
3. Early Results of Phase 2 Trial of Perifosine (KRX-0401) for the Treatment of Recurrent Malignant Gliomas Presented at the 12th Annual Scientific Meeting of Society for Neuro-Oncology
4. SuperGen to Highlight Oncology Pipeline Data in Multiple Presentations at the AACR-NCI-EORTC International Conference
5. U.S. Oncology Initiates Complete Phase Ib Trial of Brostallicin Combination Therapy in Advanced Solid Tumors
6. US Oncology to Report 2007 Third Quarter Earnings Results
7. VioQuest to Present Data on Oncology Compounds VQD-002 and Lenocta(TM) at AACR-NCI-EORTC International Meeting
8. Genomic Health Reports Inclusion of Oncotype DX(TM) in American Society of Clinical Oncology Guidelines
9. Varian Medical Systems Ranks First in Overall Service Performance in 2007 Survey of U.S. Radiation Oncology Professionals
10. Accuray Announces Four New Products at Nations Leading Radiation Oncology Meeting
11. Debiopharm and NanoCarrier Sign License and Supply Agreement for Dach-Platin Polymeric Micelle in Oncology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/29/2016)... ... April 29, 2016 , ... Shamangelic Healing, Sedona Arizona's ... brand Alpha BRAIN and New Mood Daily-Stress Formula for brain optimization and wellness ... to the store is just one more way Shamangelic Healing supports people’s quest ...
(Date:4/29/2016)... ... April 29, 2016 , ... ... awareness and author of best seller "LOVE, MEDICINE and MIRACLES") addresses touchy topics ... 2, 2016 and podcasted thereafter . Dr. Bernie Siegel, author of a ...
(Date:4/29/2016)... ... April 29, 2016 , ... ... infants born with severe congenital diaphragmatic hernia have better survival rates if surgery ... diaphragmatic hernia (CDH)—a condition where the diaphragm fails to form completely, letting abdominal ...
(Date:4/29/2016)... ... April 29, 2016 , ... World Patent ... Gyrociser, an exercise invention which aids in proper muscle development. , "The Gym ... and Creative Director of World Patent Marketing. "Globalization has threatened the future growth ...
(Date:4/29/2016)... New York, NY (PRWEB) , ... April 29, 2016 , ... New York City based ... surgery . This surgery is a very effective way to treat obstructive sleep apnea. Dr. ... , Orthognathic surgery is a procedure that involves one or both jaw bones. This ...
Breaking Medicine News(10 mins):
(Date:4/28/2016)... NEW YORK , April 28, 2016  The ... reached 275 million dollars, according to Kalorama Information and ... includes typing, immunoassays and nucleic acid testing.  The healthcare ... had made progress in developing blood collection stations and ... was made in Kalorama Information,s report, Blood ...
(Date:4/28/2016)... , April 28, 2016   Acsis , a ... that leading IT market research and advisory firm IDC ... the IDC MarketScape: Worldwide Pharmaceutical Track and Trace Software ... report provides an assessment of the capabilities and business ... trace software market. Logo - http://photos.prnewswire.com/prnh/20160427/360791LOGO ...
(Date:4/27/2016)... Schweiz, April 27, 2016 ... CEO Forums in Zürich gab Strekin AG ... Wirkstoffkandidaten STR001 zur Erhaltung des Resthörvermögens von ... bekannt. Für die umfassende Phase-II-Doppelblindstudie mit Placebo-Kontrollgruppe ... angeworben. STR001 wird während der Operation direkt ...
Breaking Medicine Technology: